Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Dailipharma from Kortrijk, company number BE0755861612, closed financial year 2025 with a result of € 3,297 after tax. For that financial year Dailipharma recorded a gross margin of € 32,184 and equity of € 74,467. Compared with financial year 2024, the result moved from € 3,727 to € 3,297. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on February 2, 2026.
€ 74,467
▲ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 3,297
▼ 12% vs 2024
Profit after tax over the fiscal year.
€ 26,408
▼ 61% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 69,467.
People and assets in 2025
€ 17,391
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 144,522
▲ 27% vs 2024
€ 32,462 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 113,345
▲ 68% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,680
▲ 71% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 19,579 | € 61,293 | € 13,601 | € 32,184 | ▲ 137% |
| Profit after taxes | € 14,753 | € 47,691 | € 3,727 | € 3,297 | ▼ 12% |
| Equity | € 19,753 | € 67,444 | € 71,170 | € 74,467 | ▲ 5% |
| Total debts | € 156,906 | € 167,966 | € 183,157 | € 259,946 | ▲ 42% |
| Cash | € 66,618 | € 67,215 | € 68,589 | € 26,408 | ▼ 61% |
| Retained profit | € 14,753 | € 62,444 | € 66,170 | € 69,467 | ▲ 5% |
| Bank debt | € 0 | € 0 | € 114,210 | € 144,522 | ▲ 27% |
| Balance sheet total | € 176,659 | € 235,409 | € 254,327 | € 334,413 | ▲ 31% |
Key figures of Dailipharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to Dailipharma?
What happened at Dailipharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 3,297 (▼ 12% vs 2024). filed late Source: NBB ↗
- New establishment in Kortrijk. KBO
- Start of the company according to the CBE. KBO
In short
From € 14,753 profit in 2022 to € 3,297 profit in 2025.
Paid € 17,843 in corporate taxes since 2022.
Best year ever: 2023, with € 47,691 profit.
A new publication or filing at Dailipharma? We notify you, reason included.
Follow DailipharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Dailipharma are Lander Tibergyn, Louis Vanhove and Mathias Vancauwenberghe. Louis Vanhove is also behind DISTINGUISHED.
Directors
According to the 2025 annual accounts
Lander Tibergyn
Director
Mathias Vancauwenberghe
Director
Establishments
Establishment units
Physical locations of this company
Doorniksestraat(Kor) 27
8500 Kortrijk
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0755.861.612
- VAT number
- BE 0755.861.612
- Registered office
- Doorniksestraat(Kor) 27, 8500 Kortrijk
- Names & denominations
- Dailipharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 October 2020
- Peppol
- Active · Active since 31 Oct 2023
- Activities · NACE
Vervaardiging van andere voedingsmiddelen, neg
Overige detailhandel in nieuwe artikelen neg
Detailhandel in elektrische huishoudapparaten